Literature DB >> 9199622

Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas.

A B Tuck1, F P O'Malley, H Singhal, K S Tonkin, J F Harris, D Bautista, A F Chambers.   

Abstract

OBJECTIVE: To examine the association between expression of osteopontin (OPN), p53, other molecular markers (Ki-67, c-erb B2, and estrogen receptor protein) and tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas of the same histology.
DESIGN: Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections. Plasma OPN level was determined by a quantitative antigen capture assay.
SETTING: The patient was seen, treated, and followed up for a period of 5 years at the London Regional Cancer Centre, Ontario, Canada. PATIENT: A 60-year-old woman presented with bilateral infiltrating mammary carcinomas of the same histologic type and grade. Bilateral mastectomy and axillary node dissection showed involvement of 3 of 12 right axillary and 0 of 11 left axillary lymph nodes. She later developed a right chest wall recurrence, followed by widespread metastatic disease to the skull, liver, and left femur.
RESULTS: The primary tumor of the right breast was OPN- and p53-positive, whereas the tumor of the left breast was negative for both markers. The development of right axillary lymph node metastases, chest wall recurrence, and distant metastases was associated in all instances with an immunohistochemical profile of high level expression of OPN and p53. Plasma assay for OPN at the time of last admission showed a markedly elevated OPN level.
CONCLUSIONS: Increased p53 expression was found to be associated with increased tumor aggressiveness. The association of increased OPN expression with increased malignancy in breast cancer is a novel finding and raises the possibility of a role for OPN in tumor progression, as well as the potential for this marker in predicting clinical aggressiveness.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199622

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  28 in total

1.  Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.

Authors:  Jason LeGrand; Eun Sung Park; Hongyang Wang; Shalu Gupta; James D Owens; Patrick J Nelson; Wendy DuBois; Thomas Bair; Siegfried Janz; J Frederic Mushinski
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

3.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

4.  Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.

Authors:  Bai Zhao; Tiemin Sun; Fanjuan Meng; Aibing Qu; Chunling Li; Hui Shen; Yu Jin; Wenxin Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-05       Impact factor: 4.553

5.  Nitric oxide-dependent osteopontin expression induces metastatic behavior in HepG2 cells.

Authors:  Hongtao Guo; Carlos E Marroquin; Philip Y Wai; Paul C Kuo
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

6.  Expression of bone sialoprotein and osteopontin in breast cancer bone metastases.

Authors:  T Ibrahim; I Leong; O Sanchez-Sweatman; R Khokha; J Sodek; H C Tenenbaum; B Ganss; S Cheifetz
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 7.  Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation.

Authors:  A O'Regan; J S Berman
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

8.  Homing of cancer cells to the bone.

Authors:  Anjali Mishra; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Cancer Microenviron       Date:  2011-08-09

9.  Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis.

Authors:  Lara H El Touny; Partha P Banerjee
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal.

Authors:  Stephen M Selkirk; Jay Morrow; Tara A Barone; Alan Hoffer; Jeffrey Lock; Anne DeChant; Saisho Mangla; Robert J Plunkett; Robert H Miller
Journal:  J Neurooncol       Date:  2007-10-11       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.